Amgen is a leading biotechnology company that focuses on the development, manufacturing, and commercialization of innovative therapeutic solutions to treat serious illnesses. The company leverages its advanced science and research capabilities to create biologic therapies that target various medical conditions, including cancer, kidney disease, and rheumatoid arthritis. Through a commitment to scientific excellence, Amgen aims to enhance patient care by providing effective treatments that improve health outcomes and quality of life. Additionally, the company engages in extensive research collaborations and partnerships, further advancing its mission to deliver groundbreaking therapies to patients around the world. Read More
Amgen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $441.95, marking a 16.5% gain...
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.91% on an annualized basis producing an average annual return of 14.92%. Currently, Amgen has a market capitalization of $241.16 billion.
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
Retail sales just fell for the first time in nine months, and consumer confidence dropped to 51. Here's what a tired shopper means for the stock market.
